TY - JOUR
T1 - Therapeutic response assessment in pancreatic ductal adenocarcinoma
T2 - society of abdominal radiology review paper on the role of morphological and functional imaging techniques
AU - Wang, Zhen J.
AU - Arif-Tiwari, Hina
AU - Zaheer, Atif
AU - Ameli, Sanaz
AU - Bhosale, Priya R.
AU - Do, Richard K.
AU - Goenka, Ajit H.
AU - Guimares, Alexander R.
AU - Sangster, Guillermo P.
AU - Soloff, Erik V.
AU - Tamm, Eric P.
AU - Zins, Marc
AU - Kambadakone, Avinash R.
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/12
Y1 - 2020/12
N2 - Abstract: Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the United States and is projected to be the second by 2030. Systemic combination chemotherapy is considered an essential first-line treatment for the majority of patients with PDA, in both the neoadjuvant and palliative settings. In addition, a number of novel therapies are being tested in clinical trials for patients with advanced PDA. In all cases, accurate and timely assessment of treatment response is critical to guide therapy, reduce drug toxicities and cost from a failing therapy, and aid adaptive clinical trials. Conventional morphological imaging has significant limitations, especially in the context of determining primary tumor response and resectability following neoadjuvant therapies. In this article, we provide an overview of current therapy options for PDA, highlight several morphological imaging findings that may be helpful to reduce over-staging following neoadjuvant therapy, and discuss a number of emerging imaging, and non-imaging, tools that have shown promise in providing a more precise quantification of disease burden and treatment response in PDA. Graphic Abstract: [Figure not available: see fulltext.]
AB - Abstract: Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the United States and is projected to be the second by 2030. Systemic combination chemotherapy is considered an essential first-line treatment for the majority of patients with PDA, in both the neoadjuvant and palliative settings. In addition, a number of novel therapies are being tested in clinical trials for patients with advanced PDA. In all cases, accurate and timely assessment of treatment response is critical to guide therapy, reduce drug toxicities and cost from a failing therapy, and aid adaptive clinical trials. Conventional morphological imaging has significant limitations, especially in the context of determining primary tumor response and resectability following neoadjuvant therapies. In this article, we provide an overview of current therapy options for PDA, highlight several morphological imaging findings that may be helpful to reduce over-staging following neoadjuvant therapy, and discuss a number of emerging imaging, and non-imaging, tools that have shown promise in providing a more precise quantification of disease burden and treatment response in PDA. Graphic Abstract: [Figure not available: see fulltext.]
KW - Computed tomography
KW - Magnetic resonance imaging
KW - Pancreatic ductal adenocarcinoma
KW - Positron emission tomography
KW - Response to treatment
UR - http://www.scopus.com/inward/record.url?scp=85091055996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091055996&partnerID=8YFLogxK
U2 - 10.1007/s00261-020-02723-z
DO - 10.1007/s00261-020-02723-z
M3 - Review article
C2 - 32936417
AN - SCOPUS:85091055996
SN - 2366-004X
VL - 45
SP - 4273
EP - 4289
JO - Abdominal Radiology
JF - Abdominal Radiology
IS - 12
ER -